AZN vs AMGN: AstraZeneca PLC vs Amgen Inc.
Side-by-side snapshot of two Healthcare companies — key metrics from our latest data. Reference only, not investment advice.
| Metric | AZN | AMGN |
|---|---|---|
| Company | AstraZeneca PLC | Amgen Inc. |
| Price | £125.94 | $366.29 |
| Market Cap | £195.32B | $197.69B |
| P/E Ratio | 25.04 | 25.51 |
| EPS | £0.05 | $14.36 |
| Dividend Yield | 1.88% | 2.75% |
| 52-Week High | £157.32 | $391.29 |
| 52-Week Low | £98.92 | $269.77 |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | LSE | NMS |
| Employees | 96,100 | 31,500 |
AstraZeneca PLC and Amgen Inc. both operate in the Healthcare sector. AZN trades at a market cap of £195.32B against AMGN's $197.69B. Valuation-wise, AZN carries a trailing P/E of 25.04 versus 25.51 for AMGN. How these figures compare depends on each company's growth profile, margins and outlook — the snapshot above is a starting point for further research, not a recommendation.
Figures are from our latest data snapshot and may not reflect current market prices. See the full profiles: AstraZeneca PLC and Amgen Inc.. This is not financial advice.
Recommended Reading & Tools
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Philip Fisher's growth-investing classic on evaluating management and moats.
Check Price →A desk whiteboard for tracking tickers, levels and ideas at a glance.
Check Price →Roger Lowenstein's definitive biography of the world's most famous investor.
Check Price →Data snapshot: 18 July 2026 (Yahoo Finance) · Page last built: